Proteostasis Therapeutics, Inc. (PTI) related to its merger with Yumanity Therapeutics. Under the terms of the agreement, Proteostasis will acquire all outstanding shares of Yumanity in exchange for newly-issued shares of Proteostasis common stock, with existing Proteostasis shareholders expected to own approximately 32.5% of the combined company.